xBxBio outlines patient-specific Virtual Heart modeling approach

xBxBio is describing a physiology-first plan for its Virtual Heart inside the company’s Connected Cardiovascular Intelligence platform. The concept is meant to link electrical activity, muscle mechanics and blood flow in a patient-specific way, while the company says the system is still under development and not cleared for clinical use.

Why it matters: - xBxBio is positioning its Virtual Heart as a different kind of cardiac model: one meant to explain how a patient’s heart works, not just how it looks. - The approach could help clinicians evaluate the relationship between electrical signals, contraction and circulation in an individual patient. - xBxBio says the platform is still in development and is not currently offered for clinical use.

What happened: - xBxBio outlined a physiology-first direction for its Virtual Heart on September 29, 2026. - The company said the model is intended to be patient-specific and part of its broader Connected Cardiovascular Intelligence platform. - The framework is designed to connect electrophysiology, myocardial mechanics and hemodynamics. - xBxBio said the release describes a scientific direction, not a completed clinical product.

The details: - Electrophysiology covers the timing and spread of electrical activation in the heart. - Myocardial mechanics covers how heart muscle deforms, contracts and relaxes. - Hemodynamics covers pressure, blood flow and interactions among the heart, valves and circulation. - xBxBio’s goal is to relate those domains using patient evidence and explicitly stated modeling assumptions. - The company said the intended output is not just several measurements shown together, but a representation of how electrical, mechanical and circulatory findings may fit together. - xBxBio says a virtual heart should be judged by the evidence supporting its behavior, not only by how convincingly it moves. - The proposed work would combine imaging-derived anatomy with electrical, functional and clinical evidence. - Patient-specific geometry alone would not determine tissue properties, activation sequence, contractile behavior or pressure conditions. - Those features would require measurement, estimation and evaluation. - Observed findings would need to stay separate from calculated quantities, estimated parameters and unmeasured properties. - Where evidence is insufficient, the model should preserve that limitation instead of implying precision through visual detail. - The company described a synthetic example in which activation findings, regional contraction measurements and flow observations could be tested for compatibility under stated assumptions. - That example is a proposed evaluation scenario, not a reported experiment or patient outcome. - The virtual heart is intended to support clinicians in developing and revisiting patient-specific recommendations within the wider platform. - The physiological representation is meant to provide context for findings and hypotheses while clinical judgment and patient circumstances remain central. - The company said the system is not intended to reproduce every property of a person’s heart or determine treatment independently. - xBxBio said evaluation must examine three levels: whether software performs its calculations, whether modeled behavior matches physiological evidence, and whether the output is useful in the intended workflow. - Agreement with data used to fit a model would not, by itself, prove performance on new observations.

Between the lines: - The messaging reflects a push to separate credible physiology from attractive visualization. - The company is also drawing a line between model fitting and real-world clinical validation, which is important in medical AI and simulation work. - By stressing uncertainty and unresolved features, xBxBio is signaling that incomplete evidence should remain visible in the model.

What’s next: - xBxBio said it welcomes discussions with clinicians, imaging specialists, electrophysiologists, computational researchers and prospective collaborators. - Background materials are available through the company’s Research and Publications page. - Scientific and media inquiries can be directed through the company’s Request a Briefing page. - xBxBio said future evaluation will need to show software performance, physiological agreement and clinical usefulness before any clinical use can be claimed. - The company’s cardiac platform and Virtual Heart remain under development and are not authorized for clinical use.

The bottom line: - xBxBio is pitching a cardiac modeling vision built around evidence, uncertainty and clinician oversight, not a finished diagnostic product.